0LTI.LSE Waters Corp.
- Market cap
- -
- P/E
- 38.8x
- P/B
- -
- ROE
- -2.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 0LTI.LSE undervalued?
Graham numberThe Graham number of Waters Corp. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Waters Corp. fundamental analysis
No fundamental analysis for Waters Corp. yet.
Waters Corp. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Waters Corp.
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments f…
Full company profileWaters Corp. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Waters Corp. annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 2.17B | 2.31B | 2.42B | 2.41B | 2.37B | 2.79B | 2.97B | 2.96B | 2.96B | 3.17B | 5.82B |
| Gross Profit | 1.29B | 1.36B | 1.43B | 1.39B | 1.34B | 1.62B | 1.72B | 1.76B | 1.71B | 1.83B | 1.87B |
| Operating Income | 637M | 673M | 746M | 723M | 678M | 829M | 887M | 818M | 852M | 893M | 68.0M |
| EBITDA | 725M | 784M | 800M | 822M | 778M | 958M | 1.01B | 1.02B | 1.04B | 1.01B | 1.08B |
| Net Income | 522M | 20.3M | 594M | 592M | 522M | 693M | 708M | 642M | 638M | 643M | -416M |
| EPS | 6.41 | 0.25 | 7.65 | 8.69 | 8.36 | 11 | 12 | 11 | 11 | 11 | -4.24 |
| Balance Sheet | |||||||||||
| Total Assets | 4.66B | 5.32B | 3.73B | 2.56B | 2.84B | 3.09B | 3.28B | 4.63B | 4.55B | 5.08B | 24.8B |
| Total Liabilities | 2.36B | 3.09B | 2.16B | 2.77B | 2.61B | 2.73B | 2.78B | 3.48B | 2.73B | 2.52B | 9.56B |
| Shareholders' Equity | 2.30B | 2.23B | 1.57B | -216M | 232M | 368M | 504M | 1.15B | 1.83B | 2.56B | 15.2B |
| Cash & Short-term Investments | 2.81B | 3.39B | 1.74B | 337M | 443M | 569M | 481M | 396M | 325M | 588M | 539M |
| Total Debt | 1.83B | 2.00B | 1.15B | 1.78B | 1.45B | 1.61B | 1.66B | 2.46B | 1.70B | 1.49B | 5.45B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 629M | 698M | 604M | 643M | 791M | 747M | 612M | 603M | 762M | 653M | 396M |
| Capital Expenditure | 95.0M | 90.5M | 96.1M | 164M | 172M | 168M | 183M | 161M | 142M | 113M | 174M |
| Free Cash Flow | 534M | 607M | 508M | 479M | 618M | 579M | 428M | 442M | 620M | 540M | 222M |
| Ratios | |||||||||||
| ROE | 22.7% | 0.9% | 37.9% | - | 224.7% | 188.5% | 140.3% | 55.8% | 34.9% | 25.1% | -2.7% |
| ROA | 11.2% | 0.4% | 15.9% | 23.2% | 18.4% | 22.4% | 21.6% | 13.9% | 14.0% | 12.6% | -1.7% |
| Net Profit Margin | 24.1% | 0.9% | 24.5% | 24.6% | 22.1% | 24.9% | 23.8% | 21.7% | 21.6% | 20.3% | -7.1% |
| Debt to Equity | 0.79x | 0.89x | 0.73x | - | 6.26x | 4.37x | 3.30x | 2.13x | 0.93x | 0.58x | 0.36x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Waters Corp. dividends
Waters Corp. has not paid dividends in the last 9 fiscal years.
Who owns Waters Corp.
- Insiders 0.10%
- Institutions 99.90%
- Public & others 0.00%
- Free float 98.1M
Waters Corp. company profile
- Company name
- Waters Corp.
- Ticker
- 0LTI.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 16,000
- Fiscal year end
- December
- Address
- 34 Maple Street, Milford, MA, United States, 01757
- Phone
- 508 478 2000
- Website
- waters.com
About Waters Corp.
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company operates through two segments, Waters and TA. The company designs, manufactures, sells, and services liquid chromatography, as well as mass spectrometry (MS) technology systems and supports products, including chromatography columns, and other consumable products. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer goods, and healthcare products, as well as for life science research; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. In addition, the company offers MS technology, which is used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. Its products are used by clinical, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company was founded in 1958 and is headquartered in Milford, Massachusetts.
Waters Corp. management
10- Dr. Udit Batra Ph.D.President, CEO & Director · born 1971
- Mr. Amol ChaubalSenior VP & CFO · born 1976
- Ms. Jianqing Y. BennettSenior Vice President of Waters Advanced Diagnostics Division · born 1970
- Mr. Mark GladwellSVP of Global Operations · born 1975
- Mr. Brook M. ColangeloSenior VP & Chief Information Officer · born 1978
- Mr. Caspar TudorHead of Investor Relations
- Ms. Keeley A. Aleman J.D.Senior VP, General Counsel, Head of Global Human Resources & Corporate Secretary · born 1977
- Ms. Kristen GarveySenior Vice President of Global Communications
- Dr. Daniel Rush Ph.D.Senior Vice President of Global Research & Strategy
- Mr. Allan JaenickeSenior Vice President of Transformation